Vir Biotechnology Q4 revenue beats estimates
Overview
Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue
Company reported a net loss for Q4, decreased compared to last year
Company announced collaboration with Astellas for prostate cancer treatment development
Outlook
Vir expects cash reserves to fund operations into Q2 2028
Result Drivers
NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment
COST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiatives
Company press release: ID:nBwbtQvVSa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $64.10 mln | $23.18 mln (6 Analysts) |
Q4 EPS |
| -$0.31 |
|
Q4 Net Income |
| -$42.9 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
The Selective Surge: Navigating the New Era of Altcoin Dominance and ETF Integration
Navigate the selective 2026 altcoin surge. Discover how Solana and XRP ETF inflows are reshaping the market, driving a "local altcoin season" despite a low index value of 41.
International Copper Prices Rise for 7 Straight Months; Will Bull Market Continue in 2026?
TradingKey - As the "king of industrial metals," every fluctuation in international copper prices impacts the nerves of global investors. In early 2026, international copper prices continued to rise, extending the upward trend from 2025 and reaching a new high above $14,500, marking seven consecutive months of gains. Meanwhile, London Metal Exchange (LME) copper prices have climbed from $7,800 per tonne in July 2025 to over $9,000 per tonne today.
Nikkei Index Heading Toward 60,000? Why Is Global Capital Betting on Sanae Takaichi? Will Japan’s Stock Market Continue to Hit New Highs in 2026?
TradingKey - In February 2026, the Tokyo stock market once again became the epicenter of global financial markets. Following a landslide victory by the Sanae Takaichi-led Liberal Democratic Party in the Lower House elections, the Nikkei 225 Index hit consecutive record highs within just a few days, targeting the 60,000-point milestone.
